Muller Danièle, Bonaiti-Pellié Catherine, Abecassis Joseph, Stoppa-Lyonnet Dominique, Fricker Jean-Pierre
Unitè de Génétique Oncologique and Laboratoire de Biologie Tumorale, Centre Régional de Lutte Contre le Cancer Paul Strauss, 67065 Strasbourg Cedex, France.
Fam Cancer. 2004;3(1):15-20. doi: 10.1023/B:FAME.0000026819.44213.df.
The purpose of this study was to determine whether two mutations detected frequently in a population of breast and/or ovarian cancer families originating from the northeastern part of France could be due to a founder effect.
83 index cases of families ascertained to have a familial breast and/or ovarian cancer history, were screened for mutations in all coding exons of the BRCA1 gene, using combined DGGE and direct sequencing. For haplotype analysis, six polymorphic markers were used for allelotyping of mutation carriers and non carriers from nine families with 3600del11 mutation and four families with G1710X mutation.
Of 83 index cases, 27 (32%) had 14 different BRCA1 mutations, one of which (G1710X), had not been reported in other populations. Two mutations were particularly common: 3600del11 in exon 11 accounted for 37% and the nonsense mutation G1710X in exon 18 for 15% of all mutations. We identified a common haplotype for each mutation suggesting a common founder for each recurrent mutation. No specific phenotype could be assigned to any of the common mutations.
These data demonstrate geographical clustering and suggest a founder effect for particular BRCA1 mutations, which identification will facilitate carrier detection in French families with breast cancer and breast and/or ovarian cancer.
本研究旨在确定在源自法国东北部的乳腺癌和/或卵巢癌家族群体中频繁检测到的两种突变是否可能归因于奠基者效应。
对83例确诊有家族性乳腺癌和/或卵巢癌病史的索引病例,使用变性梯度凝胶电泳(DGGE)和直接测序相结合的方法,对BRCA1基因的所有编码外显子进行突变筛查。对于单倍型分析,使用六个多态性标记对来自九个携带3600del11突变的家族和四个携带G1710X突变的家族的突变携带者和非携带者进行等位基因分型。
在83例索引病例中,27例(32%)有14种不同的BRCA1突变,其中一种(G1710X)在其他人群中尚未见报道。两种突变尤为常见:外显子11中的3600del11占所有突变的37%,外显子18中的无义突变G1710X占15%。我们为每种突变鉴定出一种常见单倍型,提示每种复发性突变有一个共同的奠基者。没有任何一种常见突变可对应特定的表型。
这些数据证明了地理聚集性,并提示特定BRCA1突变存在奠基者效应,这一发现将有助于在法国乳腺癌和乳腺癌和/或卵巢癌家族中检测携带者。